Literature DB >> 21676289

Oncolytic virotherapy for pancreatic cancer.

Sonia Wennier1, Shoudong Li, Grant McFadden.   

Abstract

Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21676289      PMCID： PMC3230120          DOI： 10.1017/S1462399411001876

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN： 1462-3994            Impact factor:   5.600


  119 in total

1.  Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells.

Authors:  L J Mundschau; D V Faller
Journal:  Biochimie       Date:  1994       Impact factor: 4.079

2.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

3.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.

Authors:  M A Molina; M Sitja-Arnau; M G Lemoine; M L Frazier; F A Sinicrope
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.

Authors:  Guy R Simpson; Ziqun Han; Binlei Liu; Yibing Wang; Gregor Campbell; Robert S Coffin
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

7.  Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.

Authors:  Stephan Leitner; Katrina Sweeney; Daniel Oberg; Derek Davies; Enrique Miranda; Nick R Lemoine; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

8.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

10.  Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.

Authors:  Howard L Kaufman; Seunghee Kim-Schulze; Kelledy Manson; Gail DeRaffele; Josephine Mitcham; Kang Seok Seo; Dae Won Kim; John Marshall
Journal:  J Transl Med       Date:  2007-11-26       Impact factor: 5.531
View more
  16 in total

1.  Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.

Authors:  Verena May; Susanne Berchtold; Alexander Berger; Sascha Venturelli; Markus Burkard; Christian Leischner; Nisar P Malek; Ulrich M Lauer
Journal:  Oncol Lett       Date:  2019-09-20       Impact factor: 2.967

Review 2.  Advanced-stage pancreatic cancer: therapy options.

Authors:  Jens Werner; Stephanie E Combs; Christoph Springfeld; Werner Hartwig; Thilo Hackert; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2013-04-30       Impact factor: 66.675

3.  Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.

Authors:  Marion Gayral; Hubert Lulka; Naima Hanoun; Coline Biollay; Janick Sèlves; Alix Vignolle-Vidoni; Hervé Berthommé; Pascal Trempat; Alberto L Epstein; Louis Buscail; Jean-Luc Béjot; Pierre Cordelier
Journal:  Hum Gene Ther       Date:  2015-01-19       Impact factor: 5.695

4.  Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model.

Authors:  Artur Yakimovich; Heidi Gumpert; Christoph J Burckhardt; Verena A Lütschg; Andreas Jurgeit; Ivo F Sbalzarini; Urs F Greber
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

5.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Authors:  Assia L Angelova; Svitlana P Grekova; Anette Heller; Olga Kuhlmann; Esther Soyka; Thomas Giese; Marc Aprahamian; Gaétan Bour; Sven Rüffer; Celina Cziepluch; Laurent Daeffler; Jean Rommelaere; Jens Werner; Zahari Raykov; Nathalia A Giese
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

7.  Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.

Authors:  Samantha B Kasloff; Matteo S Pizzuto; Micol Silic-Benussi; Silvia Pavone; Vincenzo Ciminale; Ilaria Capua
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

Review 8.  Viro-immune therapy: A new strategy for treatment of pancreatic cancer.

Authors:  Andrea Marie Ibrahim; Yao-He Wang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

9.  Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Authors:  Franz J Zemp; Brienne A McKenzie; Xueqing Lun; Lori Maxwell; Karlyne M Reilly; Grant McFadden; V Wee Yong; Peter A Forsyth
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.